Blepharitis News and Research

RSS
A common disorder of the eye, blepharitis, is a condition in which there is visible inflammation in the eyelids. Bacteria causes irritation and the eyelids become red and itchy. Though it does not cause permanent damage to vision, blepharitis causes discomfort to patients. Women in their peri- and post-menopausal stage are more prone to the dysfunction of the meibomian glands.
Popular eyelash treatments linked to rise in eye infections and emergency procedures

Popular eyelash treatments linked to rise in eye infections and emergency procedures

Sun Pharma receives U.S. FDA approval for CEQUA to treat patients with dry eye disease

Sun Pharma receives U.S. FDA approval for CEQUA to treat patients with dry eye disease

U-M researchers envision new ways to avoid inappropriate ER use for mild eye problems

U-M researchers envision new ways to avoid inappropriate ER use for mild eye problems

Ophthalmology expert offers tips to help relieve seasonal dry eye

Ophthalmology expert offers tips to help relieve seasonal dry eye

Philip Chapper & Co to showcase new partner products at Europe’s largest pharmaceutical trade fair

Philip Chapper & Co to showcase new partner products at Europe’s largest pharmaceutical trade fair

Center Director of Omni Eye Surgery describes promising option for managing lid disease

Center Director of Omni Eye Surgery describes promising option for managing lid disease

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

NovaBay introduces new eye care product to help patients with eyelids irritation

NovaBay introduces new eye care product to help patients with eyelids irritation

Kala Pharmaceuticals completes $22.5 million Series B financing

Kala Pharmaceuticals completes $22.5 million Series B financing

Researchers identify potential therapy for meibomian gland dysfunction

Researchers identify potential therapy for meibomian gland dysfunction

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision first quarter total revenues decrease to $2.3 million

InSite Vision first quarter total revenues decrease to $2.3 million

Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome

Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma